Masaki Shiota, Tokiyoshi Tanegashima, Shuichi Tatarano, Toshiyuki Kamoto, Hideyasu Matsuyama, Hideki Sakai, Tsukasa Igawa, Tomomi Kamba, Naohiro Fujimoto, Akira Yokomizo, et al. The effect of human leukocyte antigen genotype on survival in advanced prostate cancer treated with primary androgen deprivation therapy: the KYUCOG-1401-A study. Prostate cancer and prostatic diseases. 2024
Shotaro Nakanishi, Yumi Fukushima, Junichi Inokuchi, Tomoaki Hakariya, Hiroaki Kakinoki, Hideki Enokida, Katsuaki Chikui, Hirofumi Matsuoka, Toshitaka Shin, Shoichiro Mukai, et al. Clinicopathological characteristics of adrenocortical carcinoma in the Kyushu-Okinawa area of Japan. International journal of urology : official journal of the Japanese Urological Association. 2024
Akira Yokomizo, Masaki Shiota, Futoshi Morokuma, Masatoshi Eto, Hideyasu Matsuyama, Hiroaki Matsumoto, Toshiyuki Kamoto, Naoki Terada, Kazuya Kawahara, Hideki Enokida, et al. GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401. International journal of urology : official journal of the Japanese Urological Association. 2023
Toshiki Anami, Yuki Ibe, Lianbo Li, Yoshihiro Komohara, Hiroki Hirao, Mamoru Harada, Hiromu Yano, Yukio Fujiwara, Takanobu Motoshima, Junji Yatsuda, et al. Overexpression of SerpinB9 in non-seminomatous germ cell tumors. Medical molecular morphology. 2023. 57. 1. 68-75
Tomomi Kamba. [IV. The First Japanese Clinical Practice Guidelines on Penile Cancer 2021]. Gan to kagaku ryoho. Cancer & chemotherapy. 2023. 50. 1. 55-58
Randomized controlled trial of GnRH antagonist monotherapy versus GnRH agonist plus bicalutamide (CAB) for patients with metastatic hormone-sensitive prostate cancer (mHSPC) (KYUCOG-1401).
(JOURNAL OF CLINICAL ONCOLOGY 2022)
Searching for novel pVHL target proteins by SILAC (Stable Isotope Labeling using Amino Acids in Cell Culture)
(CANCER SCIENCE 2022)
Development of the novel TFE3 transcriptional inhibitors to target drug resistance on Xp11.2 renal cell carcinoma
(CANCER SCIENCE 2022)
High T-cell infiltration in tumor tissue predict the response to pembrolizumab in recurrent urothelial cancer
(CANCER SCIENCE 2022)